Findings · census run August 2026 · Standard v1.1

Warning letters across the field, and what happened next

Recorded August 2026 · Standard v1.1

6 of the 25 records in the ledger disclose an FDA warning letter, 7 letters in all. 6 of the 6 still trade. 0 have been halted by an FDA action. 0 of the 7 letters carry a close-out letter on the FDA index.

Criterion S8, enforcement status, records a letter and fails a seller only where an action halted the business. This piece reports the letters in aggregate: every one by number and date, what it alleges, how it was tied to the record, and what has happened since. It is not a list of flagged sellers. A letter is recorded on the seller record in full, and a record with a letter links, sorts and appears exactly as a record without one. The census below was run against Standard v1.1, on the date stated above, over every record in the ledger.

The number, with its denominator

Of the 25 records, 6 name at least one letter: Direct Meds, Eden, Hims & Hers, Ivim Health, Strut Health, Swiss Chems. 1 record carries more than one: Hims & Hers with 2. The count of sellers is therefore 6, not 7, and a census that counted letters as companies would state a finding about a company that does not exist. S8 records 0 failures across the 25 records, because no FDA action recorded here has halted a business.

What a warning letter is

The Food and Drug Administration describes its own instrument plainly. A warning letter “identifies the concern(s), such as poor manufacturing practices, problems with claims for what a product can do, or incorrect directions for use,” and “provides an opportunity for the company or individual to address FDA's concerns and requests a response with a certain timeframe.” Each of the 7 letters below asks for a written response within fifteen working days and states that failure to address the violations may result in legal action, including seizure and injunction. Seizure and injunction are the actions S8 fails on. The letter is the notice that precedes them, and it is not one of them.

FDA also publishes a close-out letter where it has evaluated a company's corrective actions and found them adequate, and states that a close-out “will not be issued based on representations that some action will or has been taken.” The index reserves a column for it. When the index was read in September 2026 it held 3,677 letters, and 417 of them carried a close-out letter in that column, so the column is populated and an empty cell is a reading rather than a gap. For the 7 letters below the cell is empty in 7 cases.

The letters, by number

Every letter was fetched from fda.gov and read in full on the date stated beneath the sources. The addressee and address are copied from the letter header; the subject is the one the index files it under; the allegation is the letter's own operative sentence, paraphrased; and the list beneath the table states the test that ties each letter to its ledger record. A name resemblance is never the test.

What each letter alleges, in one sentence, and the test that ties it to the record it is filed on.

Two kinds of letter

The index files the 7 letters under 3 subjects: 3 under “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”; 3 under “False & Misleading Claims/Misbranded (Telehealth)”; 1 under “Unapproved New Drugs/Misbranded”. The telehealth subjects turn on sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act, which concern labeling and the advertising of compounded drugs. The research-vendor subject turns on sections 505(a) and 301(d), which concern an unapproved new drug intended for human use. A labeling citation and an unapproved-drug citation are different allegations, and the subject line says which one a reader is looking at.

3 of the letters were issued on one day in September 2025, to Hims & Hers Health, Inc. dba Hims, Hims & Hers Health, Inc. dba Hers, directmeds.com, Inc. dba DirectMeds, and each names the month before as the month its website was reviewed. 2 of the letters were issued on one day in February 2026, to Strut Health, LLC dba Strut, Ivim Services LLC dba Ivim, and each names the month before as the month its website was reviewed. The index records 69 letters carrying that issue date, among them three to Eli Lilly and Company and one to Novo Nordisk Inc., the manufacturers of the brand drugs the telehealth letters compare against. A letter issued in that wave sits in the same database, on the same page, with the same date, as a letter to the manufacturer of the approved product.

What the letters allege, in two patterns

Two allegations recur across the telehealth letters. The first is a claim of sameness: that a compounded product has the same active ingredient as Ozempic, Wegovy, Mounjaro or Zepbound, which FDA reads as implying equivalence to an approved drug. It appears in the letters to Hims & Hers, Direct Meds and Strut Health. The second is a claim of authorship: that a pictured label names the seller as the compounder when a pharmacy the seller does not name did the compounding. It appears in the letters to Strut Health, Ivim Health and Eden.

The second pattern is the regulator asking the question criterion S3, pharmacy identification, asks. All three of those letters close by requesting that the company identify the entities that produce the compounded products offered on its website. The Eden letter adds a third allegation: the site described its sources as FDA-licensed 503(a) outsourcing facilities, and FDA states that it grants no such designation to a pharmacy or an outsourcing facility. The research-vendor letter is different in kind: it alleges that products labeled for research were, on the evidence of the seller's own product pages and social media, intended for human use.

What happened next

Every one of the 6 lettered records states, in its S8 basis, that the seller still trades. No record names an injunction, a consent decree, a seizure or a closure. No letter carries a close-out letter on the index, so no allegation is recorded as resolved either. A letter that has been neither closed out nor followed by an action is the ordinary state of a warning letter, and it is what every letter in this ledger is in.

How S8 records this

Under the first version of the Standard a letter failed the criterion. Version 1.1 changed that, and the changelog names the dispositions that moved: S8 re-scoped from Enforcement record to Enforcement status. A warning letter is now recorded and dated on the seller record rather than failing the criterion; the failing disposition is reserved for an action that halts the business, such as an injunction, consent decree, or seizure. Most warning letters concern marketing and labeling claims. Two dispositions changed under this revision: Direct Meds and Swiss Chems. A rule that treated every letter as a failure would tell a reader that a company under a labeling citation and a company shut down by a court are the same thing. They are not, and the ledger now records the difference.

The full roster

Every record in the ledger, with its S8 disposition and the basis recorded against it. A record with no letter states that the control letter was found in the same screening run, because an absence from a search is only meaningful when the search is proven to find what it looks for.

Sources

All 11 sources below read September 2026.

• FDA warning letter 695663 to Swisschems
• FDA warning letter 716567 to Hims & Hers Health, Inc. dba Hims
• FDA warning letter 716825 to Hims & Hers Health, Inc. dba Hers
• FDA warning letter 716822 to directmeds.com, Inc. dba DirectMeds
• FDA warning letter 721448 to Strut Health, LLC dba Strut
• FDA warning letter 721816 to Ivim Services LLC dba Ivim
• FDA warning letter 728279 to Eden Health International Inc. dba Eden
• FDA warning letter 716462 to Eli Lilly and Company, issued the same day
• FDA warning letter 716495 to Novo Nordisk Inc., issued the same day
• FDA, About Warning and Close-Out Letters
• FDA warning letter index, the full corpus searched locally

Counts are generated from the ledger at build time, so this page cannot drift from the records it summarizes. Method and null semantics: how checks are performed. This page ranks nothing, recommends nothing, and carries no partner link.

Related findings

All findings ›